Zymeworks Inc. (NYSE:ZYME) Director Purchases $546,796.29 in Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 39,029 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was bought at an average price of $14.01 per share, with a total value of $546,796.29. Following the transaction, the director now directly owns 15,578,732 shares in the company, valued at $218,258,035.32. The trade was a 0.25 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The stock was purchased at an average cost of $13.39 per share, with a total value of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The shares were purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock. The stock was purchased at an average price of $14.07 per share, for a total transaction of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 157,880 shares of Zymeworks stock. The shares were purchased at an average cost of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The stock was acquired at an average cost of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The shares were acquired at an average cost of $14.12 per share, with a total value of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The stock was acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Trading Up 3.1 %

ZYME stock opened at $14.04 on Thursday. Zymeworks Inc. has a 1-year low of $7.97 and a 1-year high of $17.70. The business’s 50-day moving average price is $14.42 and its two-hundred day moving average price is $12.57.

Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The company had revenue of $16.00 million for the quarter, compared to analyst estimates of $17.90 million. During the same quarter last year, the firm posted ($0.41) earnings per share. Zymeworks’s revenue was down 3.1% compared to the same quarter last year. As a group, analysts expect that Zymeworks Inc. will post -1.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ZYME. FMR LLC increased its position in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after acquiring an additional 1,525 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Zymeworks in the 3rd quarter valued at $47,000. Quest Partners LLC boosted its stake in Zymeworks by 8,049.6% in the 2nd quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock worth $78,000 after purchasing an additional 9,096 shares during the period. nVerses Capital LLC bought a new position in Zymeworks during the 3rd quarter worth about $79,000. Finally, MQS Management LLC bought a new position in Zymeworks during the 2nd quarter worth about $92,000. Institutional investors own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on ZYME shares. HC Wainwright reiterated a “neutral” rating and set a $12.00 target price on shares of Zymeworks in a research report on Friday, November 22nd. Citigroup upped their price objective on Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company increased their target price on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Stifel Nicolaus boosted their target price on Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Finally, Leerink Partnrs upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.17.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.